Dragon Pharma Tirzepatide Vials - Tirze-Pep 5 mg and 10 mg

Dragon Pharma Tirzepatide - Tirze-Pep Dual Incretin Vials

Dragon Pharma Tirzepatide covers the two research strengths of the Tirze-Pep line: a 5 mg vial for the low end of a titration ladder and a 10 mg vial for the upper steps. Tirzepatide is the dual GIP and GLP-1 receptor agonist known commercially as Mounjaro and Zepbound, and this vial is the lyophilised research form, not the approved injection. Buy tirzepatide vials from a GMP manufacturer with batch testing and a Certificate of Analysis on file.

• Two options - Tirze-Pep 5 mg and Tirze-Pep 10 mg lyophilised vials
• Dual GIP and GLP-1 receptor agonist (incretin peptide)
• Reference half-life 5.4 days in population pharmacokinetics of the approved form
• GMP-manufactured, HPLC-verified, COA on file per batch

Tirzepatide stimulates both the GIP and the GLP-1 receptor, which is the difference from single-agonist GLP-1 peptides such as Semaglutide. The incretin signal slows gastric emptying and increases satiety signalling, and the long half-life is what makes a weekly injection interval work in the approved product.

Variant Comparison

Both options are the same peptide; only the amount of powder in the vial differs.

Choosing the Right Formulation

Reconstitution arithmetic follows the vial you pick. A 5 mg vial with 2 ml of bacteriostatic water gives 2.5 mg per ml, while a 10 mg vial with 2 ml gives 5 mg per ml, so the same drawn volume holds double the amount. Laboratory work that mirrors the approved titration ladder moves up no faster than once every four weeks, which is the interval used for the 2.5 to 15 mg steps; a 5 mg vial suits the first steps of that ladder and a 10 mg vial the later ones. Peptides such as Retatrutide, Mazdutide and Survodutide belong to the same research family and are separate products, not additions to this one.

How Tirzepatide Works

The peptide binds GIP and GLP-1 receptors and amplifies the incretin response to a meal. In the approved injectable, weight change reached -15.0% at 5 mg, -19.5% at 10 mg and -20.9% at 15 mg over 72 weeks against -3.1% on placebo, and the gastrointestinal profile was dose-dependent: treatment discontinuation was 5.1% at 5 mg against 25% at 15 mg. Weight returned after withdrawal, with about 14% of body mass regained over 52 weeks on placebo.

Quality & Authenticity

Each batch is produced under GMP conditions and checked by independent HPLC, with the Certificate of Analysis held for the batch. Store the powder at 2-8 C away from light and the reconstituted solution refrigerated. The GLP-1 class is not on the WADA prohibited list and sits in the Monitoring Programme, while the FDA has warned about unapproved versions of these peptides.

For laboratory research only. Consult a healthcare professional before use.

Consult a healthcare professional before any cycle. Doses are common community protocols.